<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307005</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00142395</org_study_id>
    <nct_id>NCT03307005</nct_id>
  </id_info>
  <brief_title>Improving Sleep Quality in Heart Failure</brief_title>
  <official_title>Improving Sleep Quality in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poor sleep quality is common in patients with heart failure. The limited available evidence
      intimates that improving sleep quality in patients with heart failure may improve morbidity
      and quality of life in this patient population. However, there is a paucity of evidence
      assessing the use of effective pharmacologic therapies in heart failure. The
      nonbenzodiazepine, GABA receptor agonist, zolpidem, has been found to have considerable
      benefits over traditional benzodiazepines as a soporific medication. The investigators
      hypothesize that zolpidem will safely improve sleep quality in patients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-site, randomized, parallel, placebo controlled, double blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep architecture</measure>
    <time_frame>1 week</time_frame>
    <description>change in sleep latency as measured on a home sleep study measured in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep architecture</measure>
    <time_frame>1 week</time_frame>
    <description>change in total sleep time as measured on a home sleep study measured in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep architecture</measure>
    <time_frame>1 week</time_frame>
    <description>change in sleep efficiency as measured on a home sleep study measured as a percentage</description>
  </primary_outcome>
  <other_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>1 week</time_frame>
    <description>a questionnaire that assesses insomnia severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>1 week</time_frame>
    <description>a validated, disease specific, health status measure for patients with heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>1 week</time_frame>
    <description>a validated questionnaire that assesses chronic subjective sleepiness</description>
  </other_outcome>
  <other_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>1 week</time_frame>
    <description>a self report questionnaire that assess sleep quality</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sleep Disturbance</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem Tartrate</intervention_name>
    <description>Zolpidem tartrate 5 mg capsule one per night taken for 7 nights</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo capsule one per night taken for 7 nights</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-79 years old

          -  HFrEF, EF â‰¤ 45% (by echocardiography)

          -  NYHA functional class I to III

          -  Able to give written consent

          -  On goal-directed medical therapy for HF, with stable dosing of HF medications for 2
             weeks prior to enrollment

          -  No hospitalizations for HF within the past month

          -  Positive response to experiencing any of the following sleep-related symptoms at least
             once a week:

          -  Difficulty falling asleep

          -  Waking up during the night and having difficulty getting back to sleep

          -  Waking up too early in the morning and being unable to get back to sleep.

        Exclusion Criteria:

          -  Use of sedative-hypnotics, anxiolytic, or benzodiazepines within the previous 2 weeks

          -  Current treatment with other sedating medications such as opioids

          -  On therapy for pharmacological therapy for depression

          -  History of alcohol/drug dependence

          -  History of liver disease, HIV, or severe COPD

          -  On Thorazine

          -  Current use of ketoconazole

          -  Current use of tricyclic antidepressants

          -  Current use of macrolide antibiotics

          -  Current use of anticonvulsant medications

          -  Pregnancy. A urine pregnancy test will be performed to exclude pregnancy in potential
             subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rashmi Aurora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University, School of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rashmi Aurora, MD</last_name>
    <phone>410-550-4891</phone>
    <email>rnaurora@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jasmine Jaber, BA</last_name>
    <phone>410-550-4891</phone>
    <email>jjaber1@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Campus, Asthma and Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi N Aurora, MD</last_name>
      <phone>410-550-4891</phone>
      <email>rnaurora@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jasmine Jasber, BS</last_name>
      <phone>410-550-4891</phone>
      <email>jjaber1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

